Conformis - CFMS Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Conformis stock.
View analyst ratings for Conformis or view top-rated stocks.

1 analysts have issued 1 year target prices for Conformis' stock. Their CFMS stock forecasts range from $2.00 to $2.00. On average, they expect Conformis' share price to reach $2.00 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price.
View analysts' price targets for Conformis or view top-rated stocks among Wall Street analysts.

Conformis' stock was trading at $0.7610 on January 1st, 2022. Since then, CFMS stock has decreased by 63.2% and is now trading at $0.28.
View the best growth stocks for 2022 here.

Conformis saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 2,440,000 shares, a decrease of 17.0% from the June 30th total of 2,940,000 shares. Based on an average daily trading volume, of 646,100 shares, the short-interest ratio is presently 3.8 days. Approximately 1.4% of the shares of the stock are short sold.
View Conformis' Short Interest.

Conformis is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Conformis.

Conformis will be holding an earnings conference call on Tuesday, August 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Conformis, Inc. (NASDAQ:CFMS) announced its quarterly earnings data on Wednesday, November, 3rd. The medical instruments supplier reported ($0.07) EPS for the quarter, meeting analysts' consensus estimates of ($0.07). The medical instruments supplier had revenue of $14.25 million for the quarter, compared to analysts' expectations of $14.08 million. Conformis had a negative net margin of 6.83% and a negative trailing twelve-month return on equity of 6.50%. During the same quarter in the prior year, the company posted ($0.09) earnings per share.

15 employees have rated Conformis CEO Mark Augusti on Glassdoor.com. Mark Augusti has an approval rating of 55% among Conformis' employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).

(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Conformis trades on the NASDAQ under the ticker symbol "CFMS."

Conformis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (7.00%), Granite Point Capital Management L.P. (0.92%), Avidian Wealth Solutions LLC (0.47%) and Connor Clark & Lunn Investment Management Ltd. (0.31%). Company insiders that own Conformis stock include Erin Henry, J Brent Alldredge, Kenneth P Fallon III, Mark A Augusti, Mark A Augusti, Paul S Weiner and Robert S Howe.
View institutional ownership trends for Conformis.

Shares of CFMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CFMS stock can currently be purchased for approximately $0.28.

Conformis (NASDAQ:CFMS) has a market capitalization of $51.92 million and generates $99.86 million in revenue each year. The medical instruments supplier earns $-2,410,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.

Conformis employs 310 workers across the globe.

Conformis' mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The official website for Conformis is www.conformis.com. The medical instruments supplier can be reached via phone at (781) 345-9001, via email at ir@conformis.com, or via fax at 781-345-0147.